PUBLISHED DATE : Jun 2022 | Pages : 188
Fill out your details & get your free sample
The U.S. Digital Therapeutics Market Size, Share, Trends Analysis
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022-2027
188 Pages
56 Tables
74 Charts
1 Regions
1 Countries
45 Companies
4 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 8.8 Billion |
| Market Size (2021) | USD 1.5 Billion |
| CAGR (2022-2027) | 33.15% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Application & End-user |
| Geographic Analysis | U.S. |
| KEY VENDORS | 2Morrow, Akili Interactive Labs, Cognoa, Fitbit, Kaia Health, Lark Technologies, Teladoc Health, Omada Health, Pear Therapeutics, ResMed, Voluntis, WellDoc, Dario Health, Happify Health, One Drop, and Virta Health |
The U.S. digital therapeutics market is expected to grow at a CAGR of over 33% from 2022 to 2027 and is expected to cross $8 billion by 2027. Continuous research & innovation, an increase in the incidence of chronic diseases, awareness among the masses, and approval by the regulatory government will help to expand the U.S. digital therapeutics market size in the upcoming years. However, increased pharma investment and healthcare focussed start-ups are more likely to act as market drivers for the digital therapeutics market and impact and shape the future of the U.S. digital therapeutics market to a more significant extent.
Healthcare and technology have merged and created a new category of digital health known as digital therapeutics. Digital therapeutics (DTx) is a subset of digital health that delivers therapeutic interventions to patients utilizing evidence-based, clinically evaluated software for treating, managing, and preventing a broad spectrum of behavioral, mental, and physical diseases and disorders. Digital therapeutics plays a significant role in the treatment and disease management of various chronic and mental health conditions. It presents potential solutions for chronic disease management, including congestive heart failure, type 2 diabetes, Alzheimer's disease, and cancer.
Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes. DTx products incorporate advanced technology best practices for design, clinical validation, usability, and data security. Regulatory bodies must validate them to support product claims about risk, efficacy, and intended use. It empowers patients, healthcare providers, and payers with intelligent and accessible tools for addressing various conditions through high-quality, safe, and effective data-driven interventions.
Regulatory jurisdictions most frequently categorize digital therapeutics as a subset of software as a Medical Device (SaMD), a framework developed by the International Medical Device Regulators Forum (IMDRF). All DTx products qualify as SaMD, but not all SaMD products are approved as digital therapeutic. However, a dedicated FDA regulatory framework for SaMD products remains in flux. Some DTx must undergo randomized controlled trials under the premarket approval process to demonstrate safety and efficacy like traditional pharmaceuticals.
IMPACT OF COVID-19 ON DIGITAL THERAPEUTICS
After the COVID-19 pandemic broke out, the utilization of DTx applications in various fields boomed. DTx provides unique solutions to satisfy healthcare needs, reducing the danger of COVID-19 exposure during a hospital visit. The COVID-19 pandemic joined the other major drivers for the growth of DTx, such as enhanced focus on preventive healthcare, high incidence of chronic diseases, and affordable gadgets due to technological advancements. In the post-COVID era, DTx became a dominant player in the digital health market, and its scope is likely to lift the U.S. digital therapeutics market.
Entry of Several Start-ups and Rapid Surge in Funding & Investments for DTx Companies
The goal of digital therapeutics is to treat chronic conditions at scale, relieving some of the significant stressors on the medical system, such as physician shortages. With the rise in the prevalence of chronic diseases, there has been a growing awareness of digital therapeutics. Owing to the gradual adoption of DTx, several companies have emerged in the digital therapeutics market, working with extreme expertise and intent to satisfy therapeutic needs. Furthermore, U.S. digital therapeutics market saw significant funding growth in 2021, with start-ups delivering medical interventions using evidence-based software for managing and treating a broad spectrum of diseases reporting surging investments. Investments in DTx were at a record in 2020 with $1,065 million with 64 deals. DTx start-ups are likely to increase at an incredible rate, and competition is fierce for the favor of providers, payors, and employers.
Digital therapeutic solutions have caught the eye of big pharmaceutical organizations that started to invest and form strategic alliances with digital therapeutic companies. The rising need to create value beyond drug discoveries, increasing pricing pressures, and the steady incline in chronic and complex diseases all around the globe have majorly contributed to these partnerships. For instance, in early 2021, Click Therapeutics and Otsuka Pharmaceuticals announced a new remote clinical trial conducted on Verily's Project Baseline platform. In addition, many DTx companies have attracted significant venture and private equity financing to compete with traditional biotech pharma & companies developing drugs for similar indications. For instance, Pear Therapeutics developing DTx for substance and opioid use disorder raised around $139 million.
Digital therapeutics and telehealth companies can contribute to solutions more effectively than ever by leveraging data from wearables and other digital sources. These technologies can drive more profound insight, influencing patient behaviors to prevent and manage chronic conditions. With the pandemic significantly raising the adoption of telehealth and virtual care, telehealth companies are looking to digital therapeutic platforms to enhance the value of their services. For example, Aetna's telehealth business unit, Healthagen, collaborated with Welldoc and LifeScan to assess the usage and potential health benefits of OneTouch Reveal Plus.
Artificial Intelligence & Virtual Reality assisted Digital Therapeutics.
Software applications are playing a significant role in providing digital therapeutic solutions. Mobile app-based digital therapeutic programs are being delivered at a low cost and massive scale, helping prevent disease progression and saving insurers billions of dollars. Some digital therapeutics are replacing medication with behavioral-based treatment, such as apps that use visualization exercises to help people with insomnia.
For the U.S. Digital Therapeutics market, where many new and innovative applications are launched frequently, A.I. plays a significant role in driving personalization and engagement to help patients achieve better health. AI-enabled therapeutics offer diagnosis and personalized care by tailoring the treatment and anticipating needs and challenges based on the individual's behavior. Digital therapeutics coupled with artificial intelligence (A.I.) and machine learning (ML) allow more effective clinical observations and management at the population level for various health conditions. Furthermore, virtual reality in digital therapeutics is gaining significant attention. It focuses on mental health, such as studying the mental states based on brainwave patterns. It also targets the promotion of healthy lifestyles through innovative virtual coaching.
INSIGHTS BY APPLICATION
In 2021, the treatment & disease management segment accounted for more than 80% of the market share. This treatment & management market will increase its domination during the forecast period and is likely to grow at a faster growth. This segment includes managing and treating diseases like chronic care, mental health & neurological disorders using DTx. Digital therapeutics are being increasingly adopted due to the growing concern of chronic diseases. It is intended to help patients change their behaviors, often through cognitive-behavioral therapy (CBT), to successfully implement care plans for their chronic health or mental health conditions.
INSIGHTS BY END-USERS
In 2021, healthcare providers accounted for the largest share of 29.11% in the digital therapeutics market in the United States Digital Therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high-quality, safe, and effective data-driven interventions. It promises many advantages for physicians, care providers, patients, payers, employers, and other stakeholders. As primary end-users, patients are at the core of the DTx landscape. Most therapies are delivered via smartphones or tablets to patients, increasing access to care compared to traditional treatments.
Vendors dominating the U.S. digital therapeutics market are developing strategies such as partnerships, collaborations, joint ventures, mergers, and acquisitions for their growth and establishment. Major companies made successful partnerships to advance the adoption of DTx. Noom and Eversana partnered to cater to patients with chronic conditions and rare diseases and check patient adherence and engagement for long-drawn-out therapies. The U.S. digital therapeutics market consolidates with vendors indulging in strategic acquisitions and collaborations with pharmaceutical companies to enter the digital therapeutics market and extend their presence in the market. Some significant acquisitions also took place in the U.S. digital therapeutics market are:
Vendor partnerships and strong I.T. capabilities are essential to successfully implementing digital therapeutics across the healthcare value chain. Vendors need to collaborate to take digital therapeutics forward from single-use applications into system-wide integration with other infrastructures to deliver cost-effective and high-quality care to patients.
Major prominent vendors accounting for a significant share in the U.S. digital therapeutics market include 2Morrow, Akili Interactive Labs, Cognoa, Fitbit, Kaia Health, Lark Technologies, Teladoc Health, Omada Health, Pear Therapeutics, ResMed, WellDoc, Dario Health, and Happify.
Frequently Asked Questions
HOW BIG IS THE U.S. DIGITAL THERAPEUTICS MARKET?
The digital therapeutics market in the U.S. was valued at USD 1.5 billion in 2021 and is expected to reach USD 8.8 billion by 2027.
WHAT IS THE GROWTH RATE OF THE DIGITAL THERAPEUTICS MARKET IN THE UNITED STATES?
U.S. digital therapeutics market is expected to grow at a CAGR of 33.15% during 2022-2027.
WHAT ARE THE KEY COMPANIES IN THE DIGITAL THERAPEUTICS MARKET IN U.S.?
Key vendors include 2Morrow, Akili Interactive Labs, Cognoa, Fitbit, Kaia Health, Lark Technologies, Teladoc Health, Omada Health, Pear Therapeutics, ResMed, Voluntis, WellDoc, Dario Health, Happify Health, One Drop, and Virta Health.
WHAT ARE THE MAJOR DRIVERS IN THE US DIGITAL THERAPEUTICS MARKET?
The increase in adoption of healthcare applications & smart wearables, the rising importance of A.I. in digital therapeutics, and the growing demand for virtual reality in DTx are the major drivers in the U.S. digital therapeutics market.
WHAT ARE THE LATEST TRENDS & OPPORTUNITIES IN THE US DIGITAL THERAPEUTICS MARKET?
The promising pipeline of digital therapeutic solutions, the rapid surge in funding & investments in digital therapeutics, and strategic collaborations between DTx vendors and pharma & medical device companies are the latest trends & opportunities in U.S. digital therapeutics market.
The digital therapeutics market in the U.S. was valued at USD 1.5 billion in 2021 and is expected to reach USD 8.8 billion by 2027, growing at a CAGR of 33.15%.
The following factors are likely to contribute to the growth of the U.S. digital therapeutics market:
Base Year: 2021
Forecast Year: 2022-2027
The study considers a detailed scenario of the present U.S. digital therapeutics market and its market dynamics for 2022−2027. It covers a detailed overview of several industry growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Key Vendors
Other Prominent Vendors
Segmentation by Application
Segmentation by End-User
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY APPLICATION
4.3.2 MARKET SEGMENTATION BY END-USER
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
7.1.1 STEPS TO INTEGRATE DIGITAL THERAPEUTICS
7.1.2 CORE PRINCIPLES FOR DIGITAL THERAPEUTIC PRODUCTS
7.1.3 DIGITAL THERAPEUTIC PRODUCT CATEGORIES
7.1.4 SOME MAJOR MILESTONES IN DTX HISTORY
7.2 SOFTWARE AS A MEDICAL DEVICE (SAMD)
7.3 REGULATORY SCENARIO
7.4 REIMBURSEMENT SCENARIO
7.5 MAJOR FDA APPROVED DIGITAL THERAPEUTICS
7.6 IMPACT OF COVID-19 ON DIGITAL THERAPEUTICS
8 MARKET OPPORTUNITIES & TRENDS
8.1 MARKET ENTRY OF NUMEROUS DTX START-UPS
8.2 STRATEGIC COLLABORATIONS BETWEEN DTX VENDORS AND PHARMA & MEDICAL DEVICE COMPANIES
8.3 RAPID SURGE IN FUNDING & INVESTMENTS IN DIGITAL THERAPEUTICS
8.4 PROMISING PIPELINE OF DIGITAL THERAPEUTIC SOLUTIONS
8.5 TELEHEALTH PLAYERS LEVERAGING DTX PLATFORMS TO EXPAND CAPABILITIES
9 MARKET GROWTH ENABLERS
9.1 RISE IN CHRONIC DISEASES & NEED FOR CONTROLLING HEALTHCARE COSTS
9.2 INCREASED ADOPTION OF HEALTHCARE APPLICATIONS & SMART WEARABLES
9.3 ACQUISITIONS & COLLABORATIONS IN DIGITAL THERAPEUTICS
9.4 RISING IMPORTANCE OF AI IN DIGITAL THERAPEUTICS
9.5 GROWING DEMAND FOR VIRTUAL REALITY IN DTX
10 MARKET GROWTH RESTRAINTS
10.1 GROWING CONCERNS ABOUT PATIENT DATA PRIVACY
10.2 ECONOMICAL & TECHNICAL CHALLENGES INVOLVED WITH DTX
10.3 CHALLENGES WITH CLINICAL VALIDATION & STRINGENT REGULATORY GUIDELINES
11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.2.1 INSIGHTS BY APPLICATION
11.2.2 INSIGHTS BY TREATMENT & DISEASE MANAGEMENT
11.2.3 INSIGHTS BY PREVENTIVE CARE
11.2.4 INSIGHTS BY END-USERS
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY
12 APPLICATION
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
13 TREATMENT & DISEASE MANAGEMENT
13.1 MARKET OVERVIEW
13.2 MARKET SIZE & FORECAST
13.3 CHRONIC CARE
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 MENTAL HEALTH & NEUROLOGICAL DISORDERS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 OTHERS
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
14 PREVENTIVE CARE
14.1 MARKET OVERVIEW
14.2 MARKET SIZE & FORECAST
14.3 PRE-DIABETES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 WEIGHT MANAGEMENT
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 OTHERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
15 END-USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 HEALTHCARE PROVIDERS
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.4 PATIENTS/ INDIVIDUALS
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.5 PAYERS
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.6 EMPLOYERS
15.6.1 MARKET OVERVIEW
15.6.2 MARKET SIZE & FORECAST
15.7 OTHERS
15.7.1 MARKET OVERVIEW
15.7.2 MARKET SIZE & FORECAST
16 COMPETITIVE LANDSCAPE
16.1 COMPETITION OVERVIEW
16.2 MARKET SHARE ANALYSIS
17 KEY COMPANY PROFILES
17.1 2MORROW
17.1.1 BUSINESS OVERVIEW
17.1.2 PRODUCT OFFERINGS
17.1.3 KEY STRATEGIES
17.1.4 KEY STRENGTHS
17.1.5 KEY OPPORTUNITIES
17.2 AKILI INTERACTIVE LABS
17.2.1 BUSINESS OVERVIEW
17.2.2 PRODUCT OFFERINGS
17.2.3 KEY STRATEGIES
17.2.4 KEY STRENGTHS
17.2.5 KEY OPPORTUNITIES
17.3 COGNOA
17.3.1 BUSINESS OVERVIEW
17.3.2 PRODUCT OFFERINGS
17.3.3 KEY STRATEGIES
17.3.4 KEY STRENGTHS
17.3.5 KEY OPPORTUNITIES
17.4 FITBIT
17.4.1 BUSINESS OVERVIEW
17.4.2 PRODUCT OFFERINGS
17.4.3 KEY STRATEGIES
17.4.4 KEY STRENGTHS
17.4.5 KEY OPPORTUNITIES
17.5 KAIA HEALTH
17.5.1 BUSINESS OVERVIEW
17.5.2 PRODUCT OFFERINGS
17.5.3 KEY STRATEGIES
17.5.4 KEY STRENGTHS
17.5.5 KEY OPPORTUNITIES
17.6 LARK TECHNOLOGIES
17.6.1 BUSINESS OVERVIEW
17.6.2 PRODUCT OFFERINGS
17.6.3 KEY STRATEGIES
17.6.4 KEY STRENGTHS
17.6.5 KEY OPPORTUNITIES
17.7 TELADOC HEALTH
17.7.1 BUSINESS OVERVIEW
17.7.2 PRODUCT OFFERINGS
17.7.3 KEY STRATEGIES
17.7.4 KEY STRENGTHS
17.7.5 KEY OPPORTUNITIES
17.8 OMADA HEALTH
17.8.1 BUSINESS OVERVIEW
17.8.2 PRODUCT OFFERINGS
17.8.3 KEY STRATEGIES
17.8.4 KEY STRENGTHS
17.8.5 KEY OPPORTUNITIES
17.9 PEAR THERAPEUTICS
17.9.1 BUSINESS OVERVIEW
17.9.2 PRODUCT OFFERINGS
17.9.3 KEY STRATEGIES
17.9.4 KEY STRENGTHS
17.9.5 KEY OPPORTUNITIES
17.10 RESMED
17.10.1 BUSINESS OVERVIEW
17.10.2 PRODUCT OFFERINGS
17.10.3 KEY STRATEGIES
17.10.4 KEY STRENGTHS
17.10.5 KEY OPPORTUNITIES
17.11 VOLUNTIS
17.11.1 BUSINESS OVERVIEW
17.11.2 PRODUCT OFFERINGS
17.11.3 KEY STRATEGIES
17.11.4 KEY STRENGTHS
17.11.5 KEY OPPORTUNITIES
17.12 WELLDOC
17.12.1 BUSINESS OVERVIEW
17.12.2 PRODUCT OFFERINGS
17.12.3 KEY STRATEGIES
17.12.4 KEY STRENGTHS
17.12.5 KEY OPPORTUNITIES
17.13 DARIO HEALTH
17.13.1 BUSINESS OVERVIEW
17.13.2 PRODUCT OFFERINGS
17.13.3 KEY STRATEGIES
17.13.4 KEY STRENGTHS
17.13.5 KEY OPPORTUNITIES
17.14 HAPPIFY HEALTH
17.14.1 BUSINESS OVERVIEW
17.14.2 PRODUCT OFFERINGS
17.14.3 KEY STRATEGIES
17.14.4 KEY STRENGTHS
17.14.5 KEY OPPORTUNITIES
17.15 ONE DROP
17.15.1 BUSINESS OVERVIEW
17.15.2 PRODUCT OFFERINGS
17.15.3 KEY STRATEGIES
17.15.4 KEY STRENGTHS
17.15.5 KEY OPPORTUNITIES
17.16 VIRTA HEALTH
17.16.1 BUSINESS OVERVIEW
17.16.2 PRODUCT OFFERINGS
17.16.3 KEY STRATEGIES
17.16.4 KEY STRENGTHS
17.16.5 KEY OPPORTUNITIES
18 OTHER PROMINENT VENDORS
18.1 AYOGO
18.1.1 BUSINESS OVERVIEW
18.1.2 PRODUCT OFFERINGS
18.2 BEHAVR
18.2.1 BUSINESS OVERVIEW
18.2.2 PRODUCT OFFERINGS
18.3 CALIBRATE HEALTH
18.3.1 BUSINESS OVERVIEW
18.3.2 PRODUCT OFFERINGS
18.4 CANARY HEALTH
18.4.1 BUSINESS OVERVIEW
18.4.2 PRODUCT OFFERINGS
18.5 CARA CARE
18.5.1 BUSINESS OVERVIEW
18.5.2 PRODUCT OFFERINGS
18.6 CARDIORENAL
18.6.1 BUSINESS OVERVIEW
18.6.2 PRODUCT OFFERINGS
18.7 CEREBRAL
18.7.1 BUSINESS OVERVIEW
18.7.2 PRODUCT OFFERINGS
18.8 COGNIFIT
18.8.1 BUSINESS OVERVIEW
18.8.2 PRODUCT OFFERINGS
18.9 CUREAPP
18.9.1 BUSINESS OVERVIEW
18.9.2 PRODUCT OFFERINGS
18.10 FREESPIRA
18.10.1 BUSINESS OVERVIEW
18.10.2 PRODUCT OFFERINGS
18.11 GINGER
18.11.1 BUSINESS OVERVIEW
18.11.2 PRODUCT OFFERINGS
18.12 GLOOKO
18.12.1 BUSINESS OVERVIEW
18.12.2 PRODUCT OFFERINGS
18.13 KELVI
18.13.1 BUSINESS OVERVIEW
18.13.2 PRODUCT OFFERINGS
18.14 MAHANA THERAPEUTICS
18.14.1 BUSINESS OVERVIEW
18.14.2 PRODUCT OFFERINGS
18.15 MANTRA HEALTH
18.15.1 BUSINESS OVERVIEW
18.15.2 PRODUCT OFFERINGS
18.16 MERU HEALTH
18.16.1 BUSINESS OVERVIEW
18.16.2 PRODUCT OFFERINGS
18.17 METAME HEALTH
18.17.1 BUSINESS OVERVIEW
18.17.2 PRODUCT OFFERINGS
18.18 MONUMENT
18.18.1 BUSINESS OVERVIEW
18.18.2 PRODUCT OFFERINGS
18.19 NEUROTRACK TECHNOLOGIES
18.19.1 BUSINESS OVERVIEW
18.19.2 PRODUCT OFFERINGS
18.20 NIGHTWARE
18.20.1 BUSINESS OVERVIEW
18.20.2 PRODUCT OFFERINGS
18.21 NOOM
18.21.1 BUSINESS OVERVIEW
18.21.2 PRODUCT OFFERINGS
18.22 SHARECARE
18.22.1 BUSINESS OVERVIEW
18.22.2 PRODUCT OFFERINGS
18.23 SWORD HEALTH
18.23.1 BUSINESS OVERVIEW
18.23.2 PRODUCT OFFERINGS
18.24 TALKSPACE
18.24.1 BUSINESS OVERVIEW
18.24.2 PRODUCT OFFERINGS
18.25 THIRTY MADISON
18.25.1 BUSINESS OVERVIEW
18.25.2 PRODUCT OFFERINGS
18.26 TRIPP
18.26.1 BUSINESS OVERVIEW
18.26.2 PRODUCT OFFERINGS
18.27 VIDA HEALTH
18.27.1 BUSINESS OVERVIEW
18.27.2 PRODUCT OFFERINGS
18.28 VIVANTE HEALTH
18.28.1 BUSINESS OVERVIEW
18.28.2 PRODUCT OFFERINGS
18.29 WORKIT HEALTH
18.29.1 BUSINESS OVERVIEW
18.29.2 PRODUCT OFFERINGS
19 REPORT SUMMARY
19.1 KEY TAKEAWAYS
19.2 STRATEGIC RECOMMENDATIONS
20 QUANTITATIVE SUMMARY
20.1 MARKET BY APPLICATION
20.2 MARKET BY TREATMENT & DISEASE MANAGEMENT
20.3 MARKET BY PREVENTIVE CARE
20.4 MARKET BY END-USER
21 APPENDIX
21.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF THE US DIGITAL THERAPEUTICS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 PATH TO LAUNCHING DIGITAL THERAPEUTICS
EXHIBIT 4 PRODUCT CATEGORIES OF DIGITAL THERAPEUTICS
EXHIBIT 5 WORKFLOW OF A SOFTWARE AS A MEDICAL DEVICE (SAMD)
EXHIBIT 6 US FDA REGULATORY FRAMEWORK FOR DIGITAL THERAPEUTICS
EXHIBIT 7 IMPACT OF MARKET ENTRY OF NUMEROUS DTX START-UPS
EXHIBIT 8 MAJOR DIGITAL THERAPEUTIC START-UP COMPANIES IN US
EXHIBIT 9 IMPACT OF STRATEGIC COLLABORATIONS BETWEEN DTX VENDORS AND PHARMA & MEDICAL DEVICE COMPANIES
EXHIBIT 10 DIGITAL THERAPEUTICS & PHARMA DEALS BY THERAPEUTIC AREA
EXHIBIT 11 IMPACT OF RAPID SURGE IN FUNDING & INVESTMENTS IN DIGITAL THERAPEUTICS
EXHIBIT 12 DIGITAL HEALTH FUNDING IN US 2010–2020 ($ BILLION)
EXHIBIT 13 NUMBER OF DEALS IN DIGITAL HEALTH 2011–2021
EXHIBIT 14 IMPACT OF PROMISING PIPELINE OF DIGITAL THERAPEUTIC SOLUTIONS
EXHIBIT 15 LIST OF DIGITAL THERAPEUTICS PIPELINE BY STAGE OF DEVELOPMENT FOR SELECT VENDORS
EXHIBIT 16 COMPARISON OF INTERVENTIONAL DIGITAL THERAPEUTICS CLINICAL TRIALS BY INDUSTRY & ACADEMIC INSTITUTES 2014-2019
EXHIBIT 17 IMPACT OF TELEHEALTH PLAYERS LEVERAGING DTX PLATFORMS TO EXPAND CAPABILITIES
EXHIBIT 18 IMPACT OF RISE IN CHRONIC DISEASES & NEED FOR CONTROLLING HEALTHCARE COSTS
EXHIBIT 19 IMPACT OF INCREASED ADOPTION OF HEALTHCARE APPLICATIONS & SMART WEARABLES
EXHIBIT 20 IMPACT OF ACQUISITIONS & COLLABORATIONS IN DIGITAL THERAPEUTICS
EXHIBIT 21 IMPACT OF RISING IMPORTANCE OF AI IN DIGITAL THERAPEUTICS
EXHIBIT 22 IMPACT OF GROWING DEMAND FOR VIRTUAL REALITY IN DTX
EXHIBIT 23 IMPACT OF GROWING CONCERNS ABOUT PATIENT DATA PRIVACY
EXHIBIT 24 IMPACT OF ECONOMICAL & TECHNICAL CHALLENGES INVOLVED WITH DTX
EXHIBIT 25 IMPACT OF CHALLENGES WITH CLINICAL VALIDATION & STRINGENT REGULATORY GUIDELINES
EXHIBIT 26 US DIGITAL THERAPEUTICS MARKET 2021–2027 ($ MILLION)
EXHIBIT 27 US DIGITAL THERAPEUTICS MARKET BY APPLICATION
EXHIBIT 28 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT
EXHIBIT 29 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE
EXHIBIT 30 US DIGITAL THERAPEUTICS MARKET BY END-USER
EXHIBIT 31 FIVE FORCES ANALYSIS 2021
EXHIBIT 32 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 33 ANNUAL INCREMENT COST PER PERSON IN US FOR VARIOUS CONDITIONS
EXHIBIT 34 US DIGITAL THERAPEUTICS MARKET BY APPLICATION: INCREMENTAL GROWTH
EXHIBIT 35 US DIGITAL THERAPEUTICS MARKET BY APPLICATION: ABSOLUTE GROWTH
EXHIBIT 36 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT
EXHIBIT 37 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 38 MAJOR VENDORS OFFERING DIGITAL THERAPEUTICS FOR TREATMENT & DISEASE MANAGEMENT
EXHIBIT 39 US TREATMENT & DISEASE MANAGEMENT DIGITAL THERAPEUTICS MARKET 2021–2027 ($ MILLION)
EXHIBIT 40 US DIGITAL THERAPEUTICS MARKET BY CHRONIC CARE: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 US CHRONIC CARE DIGITAL THERAPEUTICS MARKET 2021–2027 ($ MILLION)
EXHIBIT 42 US DIGITAL THERAPEUTICS MARKET BY MENTAL HEALTH & NEUROLOGICAL DISORDERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 US MENTAL HEALTH & NEUROLOGICAL DISORDER DIGITAL THERAPEUTICS MARKET 2021–2027 ($ MILLION)
EXHIBIT 44 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 45 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021–2027 ($ MILLION)
EXHIBIT 46 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET
EXHIBIT 47 MAJOR VENDORS OFFERING DIGITAL THERAPEUTICS FOR PREVENTIVE CARE
EXHIBIT 48 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 49 US PREVENTIVE CARE DIGITAL THERAPEUTICS MARKET 2021–2027 ($ MILLION)
EXHIBIT 50 US DIGITAL THERAPEUTICS MARKET BY PRE-DIABETES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 51 US PRE-DIABETES DIGITAL THERAPEUTICS MARKET 2021–2027 ($ MILLION)
EXHIBIT 52 US DIGITAL THERAPEUTICS MARKET BY WEIGHT MANAGEMENT: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 53 US WEIGHT MANAGEMENT DIGITAL THERAPEUTICS MARKET 2021–2027 ($ MILLION)
EXHIBIT 54 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021–2027 ($ MILLION)
EXHIBIT 56 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 57 US DIGITAL THERAPEUTICS MARKET BY END-USER
EXHIBIT 58 BENEFITS OF DIGITAL THERAPEUTICS TO KEY STAKEHOLDERS
EXHIBIT 59 US DIGITAL THERAPEUTICS MARKET BY END-USER: INCREMENTAL GROWTH
EXHIBIT 60 US DIGITAL THERAPEUTICS MARKET BY END-USER: ABSOLUTE GROWTH
EXHIBIT 61 US DIGITAL THERAPEUTICS MARKET BY HEALTHCARE PROVIDERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 62 US DIGITAL THERAPEUTICS MARKET BY HEALTHCARE PROVIDERS 2021–2027 ($ MILLION)
EXHIBIT 63 US DIGITAL THERAPEUTICS MARKET BY PATIENTS/INDIVIDUALS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 US DIGITAL THERAPEUTICS MARKET BY PATIENTS/INDIVIDUALS 2021–2027 ($ MILLION)
EXHIBIT 65 US DIGITAL THERAPEUTICS MARKET BY PAYERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 US DIGITAL THERAPEUTICS MARKET BY PAYERS 2021–2027 ($ MILLION)
EXHIBIT 67 US DIGITAL THERAPEUTICS MARKET BY EMPLOYERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 68 US DIGITAL THERAPEUTICS MARKET BY EMPLOYERS 2021–2027 ($ MILLION)
EXHIBIT 69 US DIGITAL THERAPEUTICS MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 70 US DIGITAL THERAPEUTICS MARKET BY OTHERS 2021–2027 ($ MILLION)
EXHIBIT 71 GROWTH STRATEGIES BY TOP DIGITAL THERAPEUTIC COMPANIES
EXHIBIT 72 PURE AND DIVERSIFIED PLAYERS IN THE US DIGITAL THERAPEUTICS MARKET
EXHIBIT 73 US DIGITAL THERAPEUTICS MARKET: MAJOR VENDOR’S STRENGTH & CAPABILITY ANALYSIS
EXHIBIT 74 POSITION OF MAJOR PLAYERS IN THE US DIGITAL THERAPEUTICS MARKET
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 US FDA APPROVED DIGITAL THERAPEUTICS (2010-2021)
TABLE 4 2MORROW: MAJOR PRODUCT OFFERINGS
TABLE 5 AKILI INTERACTIVE LABS: MAJOR PRODUCT OFFERINGS
TABLE 6 COGNOA: MAJOR PRODUCT OFFERINGS
TABLE 7 FITBIT: MAJOR PRODUCT OFFERINGS
TABLE 8 KAIA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 9 LARK TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 10 TELADOC HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 11 OMADA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 12 PEAR THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 13 RESMED: MAJOR PRODUCT OFFERINGS
TABLE 14 VOLUNTIS: MAJOR PRODUCT OFFERINGS
TABLE 15 WELLDOC: MAJOR PRODUCT OFFERINGS
TABLE 16 DARIO HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 17 HAPPIFY HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 18 ONE DROP: MAJOR PRODUCT OFFERINGS
TABLE 19 VIRTA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 20 AYOGO: MAJOR PRODUCT OFFERINGS
TABLE 21 BEHAVR: MAJOR PRODUCT OFFERINGS
TABLE 22 CALIBRATE HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 23 CANARY HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 24 CARA CARE: MAJOR PRODUCT OFFERINGS
TABLE 25 CARDIORENAL: MAJOR PRODUCT OFFERINGS
TABLE 26 CEREBRAL: MAJOR PRODUCT OFFERINGS
TABLE 27 COGNIFIT: MAJOR PRODUCT OFFERINGS
TABLE 28 CUREAPP: MAJOR PRODUCT OFFERINGS
TABLE 29 FREESPIRA: MAJOR PRODUCT OFFERINGS
TABLE 30 GINGER: MAJOR PRODUCT OFFERINGS
TABLE 31 GLOOKO: MAJOR PRODUCT OFFERINGS
TABLE 32 KELVI: MAJOR PRODUCT OFFERINGS
TABLE 33 MAHANA THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 34 MANTRA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 35 MERU HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 36 METAME HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 37 MONUMENT: MAJOR PRODUCT OFFERINGS
TABLE 38 NEUROTRACK TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 39 NIGHTWARE: MAJOR PRODUCT OFFERINGS
TABLE 40 NOOM: MAJOR PRODUCT OFFERINGS
TABLE 41 SHARECARE: MAJOR PRODUCT OFFERINGS
TABLE 42 SWORD HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 43 TALKSPACE: MAJOR PRODUCT OFFERINGS
TABLE 44 THIRTY MADISON: MAJOR PRODUCT OFFERINGS
TABLE 45 TRIPP: MAJOR PRODUCT OFFERINGS
TABLE 46 VIDA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 47 VIVANTE HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 48 WORKIT HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 49 US DIGITAL THERAPEUTICS MARKET BY APPLICATION 2021–2027 ($ MILLION)
TABLE 50 US DIGITAL THERAPEUTICS MARKET BY APPLICATION 2021–2027 (%)
TABLE 51 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT 2021–2027 ($ MILLION)
TABLE 52 US DIGITAL THERAPEUTICS MARKET BY TREATMENT & DISEASE MANAGEMENT 2021–2027 (%)
TABLE 53 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE 2021–2027 ($ MILLION)
TABLE 54 US DIGITAL THERAPEUTICS MARKET BY PREVENTIVE CARE 2021–2027 (%)
TABLE 55 US DIGITAL THERAPEUTICS MARKET BY END-USER 2021–2027 ($ MILLION)
TABLE 56 US DIGITAL THERAPEUTICS MARKET BY END-USER 2021–2027 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
